Role of circulating soluble chemokines in septic shock;Papel de las quimioquinas solubles circulantes en el shock séptico

Medicina Intensiva

Volumn 37, Issue 8, 2013, Pages 510-518

  De Pablo, R ^a,b   Monserrat, J ^b   Prieto, A ^b   Alvarez Mon M ^a,b  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Acute renal failure; Acute respiratory distress syndrome; Biomarkers; Chemokines; Coagulopathy; Septic shock

Indexed keywords

CHEMOKINE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BLOOD CLOTTING DISORDER; CHEMOKINE BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; INTERLEUKIN 8 BLOOD LEVEL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA BLOOD LEVEL; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANTES BLOOD LEVEL; REFERENCE VALUE; SEPTIC SHOCK; SURGICAL WARD; SURVIVOR;

ACUTE RENAL FAILURE; ACUTE RESPIRATORY DISTRESS SYNDROME; BIOMARCADORES; BIOMARKERS; CHEMOKINES; COAGULOPATHY; COAGULOPATÍA; FRACASO RENAL AGUDO; QUIMIOQUINAS; SEPTIC SHOCK; SHOCK SÉPTICO; SÍNDROME DE DISTRÉS RESPIRATORIO AGUDO;

CHEMOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SHOCK, SEPTIC;

EID: 84885952252     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2012.09.008     Document Type: Article

References (48)

1. Vincent J.L., Sakr Y., Sprung C.L., Ranieri V.M., Reinhart K., Gerlach H., et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
2. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. Prognosis in acute organ-system failure. Ann Surg 1985, 202:685-693.
3. Hotchkiss R.S., Opal S. Immunotherapy for sepsis--a new approach against an ancient foe. N Engl J Med 2010, 363:87-89.
4. Fry D.E. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg 2012, 78:1-8.
5. McConnell K.W., Coopersmith C.M. Organ failure avoidance and mitigation strategies in surgery. Surg Clin North Am 2012, 92:307-319.
6. Krakauer T., Vilcek J., Oppenheim J.J. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGFβ, and others. Fundamental Immunology 2003, LWW.com, Philadelphia, p. 775-811. 5th ed. W. Paul (Ed.).
7. Liu S.F., Malik A.B. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006, 290:L622-L645.
8. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
9. Hack C.E., Hart M., van Schijndel R.J., Eerenberg A.J., Nuijens J.H., Thijs L.G., et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992, 60:2835-2842.
10. Lin K.J., Lin J., Hanasawa K., Tani T., Kodama M. Interleukin-8 as a predictor of the severity of bacteremia and infectious disease. Shock 2000, 14:95-100.
11. Harbarth S., Holeckova K., Froidevaux C., Pittet D., Ricou B., Grau G.E., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402.
12. De Pablo Sánchez R., Monserrat Sanz J., Prieto Martín A., Reyes Martín E., Álvarez de Mon Soto M., Sánchez García M. Balance entre citocinas pro y antiinflamatorias en estados sépticos. Med Intensiva 2005, 29:151-158.
13. De Pablo R., Monserrat J., Reyes E., Diaz-Martin D., Rodriguez Zapata M., Carballo F., et al. Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules. J Intensive Care Med 2011, 26:125-132.
14. Herzum I., Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008, 15:581-587.
15. Suberviola B., Castellanos-Ortega A., González-Castro A., García-Astudillo L.A., Fernández-Miret B. [Prognostic value of procalcitonin, C-reactive protein and leukocytes in septic shock]. Med Intensiva 2012, 36:177-184.
16. Damas P., Canivet J.L., de Groote D., Vrindts Y., Albert A., Franchimont P., et al. Sepsis and serum cytokine concentrations. Crit Care Med 1997, 25:405-412.
17. Fujishima S., Sasaki J., Shinozawa Y., Takuma K., Kimura H., Suzuki M., et al. Serum MIP-1 alpha and IL-8 in septic patients. Intensive Care Med 1996, 22:1169-1175.
18. Andaluz-Ojeda D., Bobillo F., Iglesias V., Almansa R., Rico L., Gandía F., et al. A combined score of pro- and anti- inflammatory interleukins improves mortality prediction in severe sepsis. Cytokine 2012, 57:332-336.
19. Bozza F.A., Salluh J.I., Japiassu A.M., Soares M., Assis E.F., Gomes R.N., et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007, 11:R49.
20. Mera S., Tatulescu D., Cismaru C., Bondor C., Slavcovici A., Zanc V., et al. Multiplex cytokine profiling in patients with sepsis. APMIS 2011, 119:155-163.
21. Oberhoffer M., Vogelsang H., Russwurm S., Hartung T., Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999, 37:363-368.
22. Halstensen A., Ceska M., Brandtzaeg P., Redl H., Naess A., Waage A. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J Infect Dis 1993, 167:471-475.
23. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001, 119:419S-425S.
24. Boutten A., Dehoux M.S., Seta N., Ostinelli J., Venembre P., Crestani B., et al. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1996, 153:336-342.
25. Chollet-Martin S., Jourdain B., Gibert C., Elbim C., Chastre J., Gougerot-Pocidalo M.A. Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Am J Respir Crit Care Med 1996, 154:594-601.
26. Donnelly S.C., Strieter R.M., Kunkel S.L., Walz A., Robertson C.R., Carter D.C., et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993, 341:643-647.
27. Miller E.J., Cohen A.B., Nagao S., Griffith D., Maunder R.J., Martin T.R., et al. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis 1992, 146:427-432.
28. Matthay M.A., Wiener-Kronish J.P. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis 1990, 142:1250-1257.
29. Ahlström A., Hynninen M., Tallgren M., Kuusela P., Valtonen M., Orko R., et al. Predictive value of interleukins 6, 8 and 10, and low HLA-DR expression in acute renal failure. Clin Nephrol 2004, 61:103-110.
30. Yang G., Li M.Z., Zhang Y.P. Effects of injectio reduqing on plasma IL-8 and nitric oxide levels in rabbits with endotoxin induced disseminated intravascular coagulation. Zhongguo Zhong Xi Yi Jie He Za Zhi 1996, 16:417-420.
31. Johnson K., Choi Y., DeGroot E., Samuels I., Creasey A., Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998, 160:5130-5135.
32. Zeng H., Zhang X., Tao R. Expression of interleukin-8 and its receptor in acute promyelocytic leukemia under all-trans retinoic acid treatment. Zhonghua Xue Ye Xue Za Zhi 1998, 19:346-349.
33. Møller A.S., Bjerre A., Brusletto B., Joø G.B., Brandtzaeg P., Kierulf P. Chemokine patterns in meningococcal disease. J Infect Dis 2005, 191:768-775.
34. Olszyna D.P., Prins J.M., Dekkers P.E., de Jonge E., Speelman P., van Deventer S.J., et al. Sequential measurements of chemokines in urosepsis and experimental endotoxemia. J Clin Immunol 1999, 19:399-405.
35. Mathiak G., Neville L.F., Grass G., Boehm S.A., Luebke T., Herzmann T., et al. Chemokines and interleukin-18 are up- regulated in bronchoalveolar lavage fluid but not in serum of septic surgical ICU patients. Shock 2001, 15:176-180.
36. Focà A., Berlinghieri M.C., Barreca G.S., Placanica P.M., Diana R., Liberto M.C., et al. Kinetics of IL-8, MIP-1 alpha, TNF, alpha, IL-1 beta, IL-1ra and IL-10 in human whole blood samples triggered by smooth and rough LPS. New Microbiol 1998, 21:123-130.
37. O'Grady N.P., Tropea M., Preas H.L., Reda D., Vandivier R.W., Banks S.M., et al. Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis. J Infect Dis 1999, 179:136-141.
38. Knapp S., Thalhammer F., Locker G.J., Laczika K., Hollenstein U., Frass M., et al. Prognostic value of MIP-1 alpha, TGF-beta 2, sELAM-1, and sVCAM-1 in patients with gram-positive sepsis. Clin Immunol Immunopathol 1998, 87:139-144.
39. Bajetto A., Bonavia R., Barbero S., Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002, 82:1311-1329.
40. Ellis M., al-Ramadi B., Hedström U., Frampton C., Alizadeh H., Kristensen J. Significance of the CC chemokine RANTES in patients with haematological malignancy: results from a prospective observational study. Br J Haematol 2005, 128:482-489.
41. Cavaillon J.M., Adib-Conquy M., Fitting C., Adrie C., Payen D. Cytokine cascade in sepsis. Scand J Infect Dis 2003, 35:535-544.
42. Schinkel S., Schinkel C., Pollard V., Garofallo R., Heberle H., Reisner P., et al. Effects of endotoxin on serum chemokines in man. Eur J Med Res 2005, 10:76-80.
43. Danese S., de la Motte C., Reyes B.M., Sans M., Levine A.D., Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 2004, 172:2011-2015.
44. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
45. Marshall J.C., Cook D.J., Christou N.V., Bernard G.R., Sprung C.L., Sibbald W.J. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995, 23:1638-1652.
46. Jacobs S., Zuleika M., Mphansa T. The Multiple Organ Dysfunction Score as a descriptor of patient outcome in septic shock compared with two other scoring systems. Crit Care Med 1999, 27:741-744.
47. Vincent J.L., de Mendonça A., Cantraine F., Moreno R., Takala J., Suter P.M., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800.
48. Moreno R., Vincent J.L., Matos R., Mendonça A., Cantraine F., Thijs L., et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999, 25:686-696.